Laurus Labs reports a strong jump in second-quarter FY27 profit, with consolidated net profit rising to ₹441 crore for the quarter ended September. The company says the increase is driven by growth in its CDMO business and its affordable medicines segment. Revenue for the quarter rises 33% to ₹2,206 crore, and multiple outlets report improving operating profitability, including margin expansion.
Laurus Labs also announces plans to expand its capabilities through acquisitions. It signs a definitive agreement to buy a 60% stake in Canada-based Galenvs Sciences, described as working on oligonucleotides and precision magnetic nanoparticles, with the deal subject to due diligence. The company separately signs an agreement to acquire a 52% stake in SI&C Resins, focused on peptide-resin technology, positioning this as strengthening in-house peptide manufacturing inputs and supply chain security.
Outlets emphasise different result metrics and strategic angles: some lead with the size and percentage of the profit jump, while others highlight EBITDA growth and margin expansion. Free Press Journal also provides additional context on revenue by division and broader half-year performance.
